Cas13d-mediated viral RNA degradation leads to potent antiviral control against both positive and negative sense RNA viruses
Respiratory viral infections continue to pose a substantial global health challenge, with a pressing need for effective treatment options. The rapid mutation rate of RNA viruses presents a significant risk of escape from existing treatments. Here, we harness the rapid adaptability and high sequence specificity of the RNA-targeting CRISPR-Cas13 nuclease technology to target and cleave the genome of different RNA viruses, disrupting replication and impairing propagation. We identified potent CRISPR-RfxCas13d/crRNA (Cas13d/crRNA) combinations that can efficiently restrict viral replication in both pre- and post-viral exposure treatment settings. In vitro treatment with lipid nanoparticles (LNPs) co-encapsulating Cas13d mRNA and crRNAs targeting coding and non-coding regions of positive-sense (+) RNA coronaviruses including SARS-CoV-2 effectively inhibited viral replication. In addition, both pre- and post-viral exposure treatments with the LNP-Cas13d/crRNA against the negative-sense (−) RNA Nipah virus resulted in 99% restriction of this highly pathogenic virus. Hence, the Cas13d/crRNA antiviral method holds promise as a potential therapeutic approach against severe viral infections caused by both (+) and (−) RNA viruses. Furthermore, the multi-locus targeting of viruses by Cas13d could offer a possibility to prevent virus breakthrough and increase the therapeutic arsenal against many emerging RNA viruses in the future.
Authors
- Ulrich Kalinke (ORCID: https://orcid.org/0000-0003-0503-9564)
- Martin Kohn (ORCID: https://orcid.org/0000-0002-7775-9651)
- Branka Horvat (ORCID: https://orcid.org/0000-0003-0578-7765)
- Matthias Bruhn (ORCID: https://orcid.org/0009-0008-2748-4080)
- Pimpan Sujariyakul (ORCID: https://orcid.org/0009-0008-8890-8457)
- Simon Alexander Krooss (ORCID: https://orcid.org/0000-0001-6372-395X)
- Lucia Amurri (ORCID: https://orcid.org/0000-0002-3257-3140)
- Jens Bohne (ORCID: https://orcid.org/0000-0002-2800-9934)
- Andreas Pavlou (ORCID: https://orcid.org/0000-0002-0435-459X)
- Sebastian Hook (ORCID: https://orcid.org/0009-0004-4686-4303)
- Heiner Wedemeyer
- Vanessa Hamann (ORCID: https://orcid.org/0009-0006-4835-3771)
- Marie Ruhe
- Michael Ott
- Maureen Obara
- Mathieu Iampietro
- Anna Carolina Henkel
Institutions
- Université Claude Bernard Lyon 1 (FR)
- École Normale Supérieure de Lyon (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Renji Hospital (CN)
- Medizinische Hochschule Hannover (DE)
- Helmholtz Centre for Infection Research (DE)
- Centre for Individualised Infection Medicine (DE)
- Center for Experimental and Clinical Infection Research (DE)
Publication Details
- Journal
- Molecular Therapy — Nucleic Acids
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1016/j.omtn.2026.103122
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Volkswagen Foundation
- Institut National de la Santé et de la Recherche Médicale
- Medizinischen Hochschule Hannover